complementari
oligonucleotid
primer
flank
gene
fragment
nt
encompass
polymorph
region
nt
subunit
bovin
coronaviru
spike
glycoprotein
use
enzymat
amplif
pcr
chose
four
clinic
isol
recov
case
epidem
diarrhea
neonat
calv
dairi
herd
specif
amplifi
analyz
sequenc
select
genom
area
nucleotid
sequenc
analysi
four
clinic
isol
indic
gene
fragment
highli
conserv
also
compar
gene
sequenc
bcv
isol
publish
correspond
sequenc
bcvmeb
refer
strain
high
degre
similar
demonstr
virus
delet
insert
observ
variat
identifi
consist
nucleotid
substitut
differ
nucleotid
amino
acid
aa
distribut
randomli
entir
sequenc
rather
cluster
polymorph
region
four
sporad
aa
chang
locat
antigen
domain
ii
aa
residu
correl
vari
antigen
observ
among
bcv
isol
react
mab
direct
glycoprotein
mebu
strain
mutat
seem
fix
isol
mr
rekik
dea
n
matrix
glycoprotein
spike
protein
hemagglutininesteras
kda
glycoprotein
often
posttransl
cleav
hostcel
proteas
two
fragment
respect
correspond
nand
ctermin
subunit
proteolyt
cleavag
may
enhanc
effect
viral
infect
fusion
activ
subunit
contain
antigen
domain
respons
induc
neutral
antibodi
appear
elicit
product
monoclon
antibodi
mab
display
highest
neutral
activ
competit
elisa
test
use
anti
mab
suggest
exist
least
four
independ
antigen
domain
b
c
subunit
antigen
site
associ
neutral
activ
alter
protein
result
chang
viral
antigen
demonstr
neutralizationescap
mutant
select
pressur
mab
specif
protein
bcv
highli
polymorph
region
subunit
bcv
aa
residu
mous
hepat
viru
type
aa
residu
identifi
region
demonstr
undergo
delet
point
mutat
select
neutral
mab
mutant
virus
display
decreas
virul
suggest
polymorph
region
may
directli
involv
viral
pathogen
recent
comparison
bcv
isol
use
polyclon
antisera
mab
direct
glycoprotein
mebu
strain
confirm
close
antigen
relationship
also
reveal
assign
least
three
distinct
antigen
subgroup
present
studi
analys
nucleotid
nt
sequenc
gene
fragment
encompass
highli
polymorph
region
proteolyt
cleavag
site
serolog
distinct
bcv
isol
compar
homolog
sequenc
mebu
refer
strain
materi
method
cell
virus
bovin
coronaviru
bcv
import
caus
acut
enter
newborn
calv
recent
report
suggest
bcv
also
respons
upper
respiratori
tract
ill
grow
calv
winter
dysenteri
hemorrhag
enter
chronic
shed
adult
cattl
viral
particl
mostli
spheric
envelop
diamet
around
nm
display
two
fring
surfac
project
viral
genom
consist
larg
singlestrand
rna
posit
polar
approxim
kb
length
encod
four
major
structur
protein
phosphonucleoprotein
cell
cultureadapt
mebu
strain
bcv
obtain
american
type
cultur
collect
atcc
rockvil
md
prototyp
bcv
strain
origin
isol
bovin
fetal
kidney
cell
diarrhea
fluid
calf
viral
isol
bcq
bcq
bcq
bcq
recov
winter
clinic
case
epidem
diarrhea
newborn
calv
affect
dairi
herd
locat
four
differ
geograph
area
commerci
bcv
vaccin
appli
herd
year
preceed
emerg
clinic
case
variou
bcv
isol
could
differenti
serolog
indirect
immunofluoresc
hemagglutinationinhibit
seroneutr
competit
elisa
test
use
mab
direct
protein
prototyp
mebu
strain
present
studi
bcv
strain
passag
five
time
human
rectal
tumor
cell
presenc
uml
bovin
pancreat
trypsin
extracellular
viron
purifi
supernat
infect
cell
cultur
differenti
isopycn
ultracentrifug
sucros
gradient
previous
describ
viral
rna
extract
follow
guanidinium
isothiocyanateacid
phenol
method
briefli
gl
purifi
viru
resuspend
vortex
vigor
gl
solut
guanidinium
isothiocyan
sodium
citrat
sarkosyl
acid
phenol
treatment
aqueou
phase
remov
rna
precipit
isopropanol
rna
pellet
wash
ethanol
dissolv
lal
rnasefre
water
store
oligonucleotid
primer
use
rtpcr
assay
chose
basi
previous
publish
sequenc
mebu
strain
bcv
emblgen
bank
access
primer
oligo
sl
complementari
sequenc
posit
gene
oligo
sla
correspond
antisens
sequenc
posit
gene
amplif
primer
pair
flank
gene
fragment
sib
encod
neutral
epitop
proteolyt
cleavag
site
order
clone
pcr
product
use
cloneamp
system
gibco
brl
gaithersburg
md
follow
sequenc
incorpor
end
amplif
primer
sn
cua
cua
asn
cau
cau
cauy
oligonucleotid
synthes
incorpor
dtmp
termini
carri
autom
dna
synthes
pharmacia
biotech
inc
baie
durf
qc
canada
prior
pcr
amplif
target
rna
convert
cdna
use
revers
transcriptas
rt
sla
primer
rt
reaction
contain
gl
pcr
buffer
prig
triton
lpl
contain
unit
rna
guard
pharmacia
biotech
inc
gl
mm
dntp
gl
mm
gl
pmol
antisens
primer
gl
extract
viral
rna
total
reaction
volum
obtain
ad
steril
depctreat
distil
water
heat
min
min
unit
mulv
rt
ad
pharmacia
biotech
inc
mixtur
incub
min
rt
reaction
stop
heat
min
store
volum
gl
pcr
reaction
mix
ad
gl
cdna
mix
final
pl
volum
contain
mm
ph
mm
mm
gelatin
sl
sla
primer
unit
taq
dna
polymeras
bio
la
jolla
ca
usa
overlay
gl
miner
oil
amplif
carri
dna
thermal
cycler
perkin
elmer
follow
cycl
program
denatur
min
anneal
rain
elong
min
total
cycl
perform
final
polymeris
step
min
follow
amplif
gl
final
product
analyz
agaros
gel
tbe
buffer
ph
boric
acid
mm
edta
stain
ethidium
bromid
pcr
product
ligat
pamp
vector
use
cloneamp
system
gibco
brl
ligat
mixtur
use
transform
compet
cell
e
coli
gibco
brl
follow
manufactur
direct
dna
sequenc
perform
dideoxynucleotid
chaintermin
method
follow
procedur
outlin
instruct
sequenc
kit
pharmacia
biotech
inc
sequenc
addit
primer
use
sequenc
sib
fragment
assess
error
rate
revers
transcriptas
taqdna
polymeras
clone
differ
cdna
synthesi
pcr
event
sequenc
error
gener
polymeras
avoid
sequenc
clone
dna
strand
direct
sequenc
analys
comput
program
nucleotid
sequenc
access
number
emblgenebankddbj
follow
complet
nucleotid
nt
deduc
amino
acid
aa
sequenc
four
clinic
bcv
isol
align
compar
fig
gene
fragment
bp
long
encod
antigen
domain
ii
identifi
within
aa
residu
polymorph
region
locat
aa
residu
proteolyt
cleavag
site
begin
aa
degre
homolog
sequenc
conserv
nucleotid
deduc
aa
sequenc
gene
fragment
analys
use
microcomput
program
genework
isol
possess
least
nt
sequenc
ident
pair
comparison
howev
nt
sequenc
gene
fragment
conserv
thu
distantli
relat
sequenc
demonstr
high
degre
similar
variat
observ
consist
point
mutat
appar
occur
random
fifti
percent
nucleotid
substitut
locat
third
posit
respect
codon
therefor
repres
translat
silent
mutat
result
thirteen
aa
chang
among
four
isol
similar
deduc
aa
sequenc
aa
differ
pair
comparison
distant
aa
differ
four
potenti
nlink
glycosyl
site
predict
case
fragment
four
bcv
isol
glycosyl
site
locat
downstream
polymorph
fig
align
deduc
amino
acid
sequenc
gene
fragment
four
bcv
isol
two
refer
strain
bcvmeb
polymorph
region
aa
residu
written
bold
face
proteolyt
cleavag
site
aa
residu
underlin
potenti
nlink
glycosyl
site
doubl
underlin
sequenc
refer
strain
bcvmeb
written
full
chang
amino
acid
residu
indic
sequenc
strain
region
antigen
domain
ii
twentysix
cystein
residu
conserv
among
isol
illustr
fig
complet
nt
sequenc
four
clinic
bcv
isol
align
compar
homolog
sequenc
mebu
bcvmeb
bcvf
refer
strain
level
nt
sequenc
ident
fragment
four
bcv
isol
bcvmeb
strain
respect
contrast
polymorph
region
nt
seem
conserv
among
bcv
isol
frameshift
delet
insert
non
sens
mutat
observ
variat
among
sequenc
consist
nt
substitut
repres
sequenc
differ
nucleotid
distribut
randomli
entir
sequenc
rather
cluster
polymorph
region
also
reflect
deduc
aa
sequenc
fig
aa
residu
immedi
upstream
polymorph
region
almost
complet
conserv
among
isol
howev
aa
substitut
found
residu
polymorph
region
fact
aa
chang
occur
almost
ident
locat
suggest
differ
may
signific
aa
residu
aa
immedi
downstream
hypervari
region
shown
part
antigen
domain
ii
recogn
neutral
mab
region
total
conserv
among
bcv
isol
test
twentysix
cystein
residu
identifi
perfectli
conserv
among
isol
five
remain
differ
residu
upstream
proteolyt
cleavag
site
repres
variabl
seem
uniqu
isol
residu
chang
consist
phe
leu
asp
f
bcvli
bcvvacc
bcvqueb
length
horizont
line
connect
one
sequenc
anoth
proport
estim
genet
distanc
sequenc
val
iie
ser
thr
ile
result
loss
one
four
potenti
nlink
glycosyl
site
identifi
case
fragment
bcv
isol
residu
substitut
lie
ser
thr
ile
also
result
increas
hydrophil
fig
surfac
probabl
region
phylogenet
tree
fig
show
relationship
four
clinic
bcv
isol
publish
homolog
sequenc
bcvmeb
bcvli
bcvvacc
base
fragment
gene
homolog
sequenc
bcvqueb
cell
cultureadapt
enteropathogen
strain
isol
also
includ
comparison
phylogenet
analys
unweight
pair
group
method
arithmet
mean
genework
classifi
recent
clinic
isol
distinct
sublineag
third
region
examin
contain
code
sequenc
proteolyt
cleavag
site
prototyp
bcv
cleavag
site
sequenc
consist
compar
sequenc
analysi
bcv
isol
six
residu
krrsrr
begin
aa
predict
cleavag
aa
cleavag
argala
bond
host
cell
trypsinlik
enzym
gener
subunit
protein
sequenc
predict
proteolyt
cleavag
site
krrsrr
conserv
among
isol
studi
howev
three
clinic
bcv
isol
examin
modif
aa
proxim
cleavag
site
isol
ser
chang
immedi
upstream
cleavag
site
consid
complex
pathogen
tropism
bcv
coronavirus
turkey
coronaviru
human
coronaviru
compar
analysi
differ
clinic
isol
probabl
produc
meaning
result
howev
accumul
data
genom
antigen
character
immunodomin
function
region
select
sequenc
analysi
present
studi
chose
four
bcv
isol
recov
case
epidem
diarrhea
neonat
calv
dairi
herd
analyz
sequenc
select
genom
area
code
immunolog
function
import
domain
nucleotid
sequenc
analysi
four
clinic
isol
indic
sib
gene
fragment
highli
conserv
compar
prototyp
bcvmeb
strain
gene
fragment
isol
differ
highest
concentr
nt
diverg
locat
polymorph
region
region
greater
nt
ident
prototyp
mebu
strain
appar
differ
nt
distribut
randomli
sequenc
mutat
differ
effect
encod
aa
sequenc
sequenc
mutat
silent
contrast
polymorph
region
nt
substitut
result
chang
aa
residu
deduc
aa
sequenc
conserv
among
strain
howev
polymorph
region
conserv
recent
comparison
gene
sequenc
six
highli
virul
includ
avirul
includ
bcvmeb
bcvqueb
strain
reveal
sequenc
ident
pair
comparison
substitut
occur
subunit
distribut
randomli
entir
sequenc
polymorph
region
almost
complet
conserv
among
strain
except
virul
strain
present
studi
closer
genom
related
demonstr
strain
four
clinic
bcv
isol
least
twelv
aa
substitut
identifi
virul
avirul
bcvmeb
bcvqueb
group
highli
polymorph
region
peptid
fig
suggest
aa
chang
particular
region
glycoprotein
may
relat
bcv
virul
howev
result
obtain
exclud
otherregion
bcv
genom
may
also
involv
virul
tissu
tropism
previous
demonstr
antigen
domain
ii
identifi
within
aa
residu
function
immunolog
import
epitop
map
domain
capabl
induc
neutral
antibodi
therefor
repres
target
immunolog
pressur
antigen
domain
togeth
polymorph
region
demonstr
variabl
among
clinic
isol
although
number
aa
substitut
rel
small
fact
substitut
appear
cluster
hypervari
region
gene
suggest
differ
may
signific
present
data
agreement
recent
find
use
variou
immunolog
assay
shown
four
bcv
isol
test
react
differ
neutral
mab
direct
subunit
mebu
strain
three
bcv
isol
examin
could
differenti
prototyp
bcvmeb
strain
nt
sequenc
proxim
proteolyt
cleavag
site
isol
ala
ser
chang
residu
immedi
upstream
cleavag
site
chang
maintain
number
pair
basic
residu
prototyp
sequenc
chang
amino
acid
proxim
cleavag
site
ha
molecul
influenza
viru
demonstr
modul
cleavabl
addit
chang
phe
ser
immedi
follow
proteolyt
cleavag
site
f
protein
sendai
viru
confer
acquisit
suscept
plasmin
cleavag
suggest
region
f
protein
contigu
cleavag
site
also
affect
cleavabl
interf
efficaci
host
proteas
involv
matur
viral
envelop
glycoprotein
howev
present
studi
ala
ser
chang
immedi
follow
cleavag
site
glycoprotein
three
quebec
bcv
isol
appear
modul
cleavabl
correl
found
substitut
rate
viral
replic
type
cytopath
chang
induc
cell
data
shown
genom
variat
identifi
present
studi
seem
repres
characterist
featur
bcv
isol
consid
fact
isol
passag
five
time
find
limit
ident
bcv
isol
possibl
sequenc
data
contain
aa
substitut
aris
cell
cultur
passag
may
exclud
howev
aa
substitut
may
occur
case
bcvmeb
bcvqueb
isol
numer
passag
done
cell
line
heterolog
anim
speci
human
rectal
adenocarcinoma
cell
line
report
suscept
permiss
human
canin
turkey
enter
coronavirus
human
cell
line
grow
cultur
tightli
pack
coloni
cell
retain
characterist
matur
enterocyt
adapt
field
strain
enter
coronavirus
celt
line
usual
requir
passag
rna
virus
expect
numer
cell
cultur
passag
result
genom
variat
may
occur
point
mutat
randomli
distribut
throughout
entir
viru
genom
rather
cluster
specif
genom
region
present
studi
sequenc
heterogen
locat
mostli
polymorph
region
glycoprotein
summari
data
shown
clinic
bcv
isol
genet
diverg
refer
strain
polymorph
region
demonstr
high
variabl
antigen
well
genet
relationship
among
current
circul
strain
bcv
provid
use
inform
determin
appropri
composit
coronavirus
vaccin
continu
surveil
virus
necessari
detect
emerg
new
lineag
bcv
alter
antigen
properti
assur
futur
vaccin
contain
appropri
strain
bcv
